Physician profile
Caroline Doo
NPI 1750736898
$1,827.81
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $117 · 2021: $254 · 2022: $276 · 2023: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $124.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $804.97 | 2019-2023 | Rinvoq |
| Galderma Laboratories, L.P. | $146.00 | 2019 | |
| Kerecis Limited | $140.34 | 2022 | |
| Kyowa Kirin, INC. | $122.66 | 2019 | |
| Amgen INC. | $118.04 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $98.13 | 2019 | |
| Allergan, INC. | $97.33 | 2019 | |
| Lilly USA, LLC | $64.05 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $57.97 | 2021 | |
| Pfizer INC. | $57.29 | 2019-2022 | |
| Leo Pharma INC. | $45.51 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $22.09 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.74 | 2021 | |
| Ucb, INC. | $19.67 | 2020 | |
| Celgene Corporation | $14.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Doo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.